|
Market Research Report
Boehringer Ingelheim: Pipeline * Products * Performance * Potential
|
Boehringer Ingelheim:
Pipeline * Products * Performance * Potential published by Espicom Business Intelligence in September, 2009. This report consists of Pages: 120 and the price starts from US $ 1040.
Abstract
Pharmaceutical company intelligence reports from Espicom provide a full review
of the company' s activities together with five-year sales forecasts for its
key products. The company' s financial performance is covered in-depth, from
its latest results to a complete analysis of its latest full fiscal year and
an outlook for the future. A section on company strategy covers mergers,
acquisitions and divestitures, key agreements, products and R&D. An overview
of key products and R&D is followed by a comprehensive review of the company' s
product portfolio and research and development pipeline by therapeutic area.
In addition, supplementary appendices provide more in-depth information on
financials, agreements and corporate events.
Table of Contents
EXECUTIVE SUMMARY
A detailed and comprehensive overview of current financial position, company
strategy, product and pipeline analysis.
THERAPEUTIC AREA FOCUS
- Key product analysis and forecasting
- Respiratory
- Combivent (ipratropium bromide+albuterol)
- Spiriva (tiotropium bromide)
- Cardiovascular
- Aggrenox (dypyridamole+acetylsalicylic acid)
- Micardis (telmisartan)
- Pradaxa (dabigatran)
- Urology
- Flomax/Alna (tamsulosin)
- Central Nervous System
- Cymbalta/Xeristar (duloxetine)
- Sifrol/Mirapex/Mirapexin (pramipexole)
- Virology
- Aptivus (tipranavir)
- Viramune (nevirapine)
OPERATIONAL DATA
- A wealth of background and detail
- A full 5-year financial performance assessment
- Key corporate events
- Key agreements
- Infrastructure
- Subsidiaries and joint ventures
|
